Mr. Swapan Kakumanu reports

NETRAMARK ANNOUNCES PRIVATE PLACEMENT FINANCING

Netramark Holdings Inc. has arranged a non-brokered private placement financing of a minimum of 7.5 million units of the company for aggregate gross proceeds of not less than $1.5-million.

Each unit will consist of one common share in the capital of the company and one common share purchase warrant. Each warrant will entitle the holder thereof to acquire, subject to adjustment in certain events, one common share in the capital of the company at an exercise price of 35 cents for a period of two years from the closing date of the offering. After the first anniversary of the issuance of the warrants, the corporation may accelerate the expiry date of the warrants if the daily volume weighted average trading price of the common shares of the company on the Canadian Securities Exchange is at or greater than $1 for 10 consecutive trading days.

Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106, Prospectus Exemptions, the units issuable pursuant to the offering will be offered for sale to purchasers resident in Canada (other than Quebec) pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106. Because the offering is being completed pursuant to the listed issuer financing exemption, the securities issued to investors under the offering will not be subject to a hold period pursuant to applicable Canadian securities laws.

In connection with the offering, the company may pay a fee equal to 6.0 per cent of the gross proceeds raised by registered dealers and issue warrants to the registered dealers equal to 6.0 per cent of the number units sold by such dealers. The finder warrants will have substantially the same terms and conditions as the warrants.

There is an offering document related to the offering that can be accessed under the company's profile on SEDAR+ and on the company's website. Prospective investors should read this offering document before making an investment decision.

Assuming a minimum offering, the company intends to use the net proceeds of the offering for building a sales pipeline based on established leads, and for working capital and general corporate expenses. See the offering document for more information on the intended use of proceeds.

The closing of the offering is expected to occur on or about Sept. 19, 2023, or such other date or dates as the company may determine.

About Netramark Holdings Inc.

Netramark is a company focused on being a leader in the development of artificial intelligence (AI)/machine learning (ML) solutions targeted at the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows Netramark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that Netramark can work with much smaller data sets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

We seek Safe Harbor.